Charles River Laboratories has expanded its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited. The license, coupled with the existing license through the Broad Institute of MIT and Harvard, allows Charles River to offer custom in vivo and in vitro genome editing. “The addition of a license from ERS provides our clients with a robust CRISPR/Cas9 gene-editing platform,” said Dr. Iva Morse, corporate vice president, chief scientific officer, Global Research Mo...